[Safety of tirofiban in patients with acute cerebral infarct receiving endovascular therapy]
- PMID: 29256229
- PMCID: PMC10396887
- DOI: 10.3785/j.issn.1008-9292.2017.08.09
[Safety of tirofiban in patients with acute cerebral infarct receiving endovascular therapy]
Abstract
Objective: To investigate the effect of tirofiban on hemorrhagic transformation and neurological outcome in patients with acute cerebral infarct treated with endovascular therapy.
Methods: One hundred and fifteen patients with acute cerebral infarct who received endovascular stent mechanical thrombectomy in the Second Affiliated Hospital, Zhejiang University School of Medicine during October 2013 and April 2017 were included in the study. Among 115 patients, 30 received tirofiban treatment. Hemorrhagic transformation and neurological outcomes were assessed using the ECASS Ⅱ criteria and modified Rankin scale (mRS), respectively. Unfavorable outcome was defined as mRS>2. Binary logistic regression model was used to analyze the independent predictors of hemorrhagic transformation and neurological outcome.
Results: Binary logistic regression analysis showed that tirofiban treatment did not increase the risk of hemorrhagic transformation (OR=0.437, 95% CI:0.168-1.132, P>0.05); baseline NIHSS (OR=1.136, 95% CI:1.014-1.273, P<0.05), recanalization (OR=0.060, 95% CI:0.010-0.365, P<0.01), hypertension (OR=4.233, 95% CI:1.320-13.570, P<0.05) and onset to treatment time(OR=1.006, 95% CI:1.001-1.011, P<0.05) were independently associated with unfavorable outcome, while such association was not observed in tirofiban treatment (OR=1.923, 95% CI:0.536-6.568, P>0.05).
Conclusions: Tirofiban appears to be safe for patients with acute cerebral infarct receiving endovascular therapy.
目的: 探讨急性缺血性卒中患者血管内治疗后使用替罗非班的安全性及预后分析。
方法: 回顾性分析2013年10月至2017年4月在浙江大学医学院附属第二医院接受静脉溶栓桥接动脉取栓或直接动脉取栓的急性缺血性卒中患者115例的临床资料。根据患者术后24 h内是否使用替罗非班治疗分为替罗非班组(30例)和对照组(85例)。参照欧洲协作性急性卒中研究(ECASS)Ⅱ标准评估24 h内的出血转化,治疗后3个月时改良Rankin量表(mRS)超过2分定义为预后不优。采用二元logistic回归分析治疗后使用替罗非班是否独立影响患者出血转化和3个月临床预后。
结果: 二元logistic回归分析提示,替罗非班治疗不增加出血转化的风险( OR=0.437,95% CI:0.168~1.132, P>0.05);患者基线美国国立卫生研究院卒中量表(NIHSS)评分( OR=1.136,95% CI:1.014~1.273, P < 0.05)、血管再通( OR=0.060,95% CI:0.010~0.365, P < 0.01)、高血压( OR=4.233,95% CI:1.320~13.570, P < 0.05)和起病至治疗时间( OR=1.006,95% CI:1.001~1.011, P < 0.05)与临床预后不优独立相关,而替罗非班治疗与临床预后不优无独立相关性( OR=1.923,95% CI:0.536~6.568, P>0.05)。
结论: 急性缺血性卒中患者血管内治疗后使用替罗非班不会增加出血转化的风险。
Similar articles
-
Safety and efficacy of tirofiban combined with endovascular treatment in acute ischaemic stroke.Eur J Neurol. 2019 Aug;26(8):1105-1110. doi: 10.1111/ene.13946. Epub 2019 Mar 19. Eur J Neurol. 2019. PMID: 30793464
-
Predictors of outcome in large vessel occlusion stroke patients with intravenous tirofiban treatment: a post hoc analysis of the RESCUE BT clinical trial.BMC Neurol. 2024 Jul 1;24(1):227. doi: 10.1186/s12883-024-03733-w. BMC Neurol. 2024. PMID: 38956505 Free PMC article.
-
Intraarterial Versus Intravenous Tirofiban as an Adjunct to Endovascular Thrombectomy for Acute Ischemic Stroke.Stroke. 2020 Oct;51(10):2925-2933. doi: 10.1161/STROKEAHA.120.029994. Epub 2020 Sep 16. Stroke. 2020. PMID: 32933416
-
Safety and Efficacy of Tirofiban in Acute Ischemic Stroke Patients Receiving Endovascular Treatment: A Meta-Analysis.Cerebrovasc Dis. 2020;49(4):442-450. doi: 10.1159/000509054. Epub 2020 Jul 30. Cerebrovasc Dis. 2020. PMID: 32731250
-
The Application of Tirofiban in the Endovascular Treatment of Acute Ischemic Stroke: A Meta-Analysis.Cerebrovasc Dis. 2021;50(2):121-131. doi: 10.1159/000512601. Epub 2021 Jan 5. Cerebrovasc Dis. 2021. PMID: 33401276 Review.
References
-
- 中华医学会神经病学分会脑血管病学组急性缺血性脑卒中诊治指南撰写组 中国急性缺血性脑卒中诊治指南2010. http://group.medlive.cn/topic/3714. 中华神经科杂志. 2010;43(2):146–153. [中华医学会神经病学分会脑血管病学组急性缺血性脑卒中诊治指南撰写组.中国急性缺血性脑卒中诊治指南2010[J].中华神经科杂志, 2010, 43(2):146-153]
-
- 赵 伟, 侯 延伟, 张 合亮, et al. 基底动脉闭塞患者静脉溶栓和联合机械取栓的差异性研究. http://www.cnki.com.cn/Article/CJFDTotal-LNXG201602022.htm. 中华老年心脑血管病杂志. 2016;18(2):179–181. [赵伟, 侯延伟, 张合亮, 等.基底动脉闭塞患者静脉溶栓和联合机械取栓的差异性研究[J].中华老年心脑血管病杂志, 2016, 18(2):179-181]
-
- CAMPBELL B C, MITCHELL P J, KLEINIG T J, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med. 2015;372(11):1009–1018. doi: 10.1056/NEJMoa1414792. [CAMPBELL B C, MITCHELL P J, KLEINIG T J, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection[J]. N Engl J Med, 2015, 372(11):1009-1018.] - DOI - PubMed
-
- 中国卒中学会重症脑血管病分会专家撰写组 急性缺血性脑卒中血管内治疗术后监护与管理中国专家共识. http://guide.medlive.cn/guidelinesub/3951. 中华医学杂志. 2017;97(3):162–172. [中国卒中学会重症脑血管病分会专家撰写组.急性缺血性脑卒中血管内治疗术后监护与管理中国专家共识[J].中华医学杂志, 2017, 97(3):162-172]
-
- BAIK S K, OH S J, PARK K P, et al. Intra-arterial tirofiban infusion for partial recanalization with stagnant flow in hyperacute cerebral ischemic stroke. Interv Neuroradiol. 2011;17(4):442–451. doi: 10.1177/159101991101700408. [BAIK S K, OH S J, PARK K P, et al. Intra-arterial tirofiban infusion for partial recanalization with stagnant flow in hyperacute cerebral ischemic stroke[J]. Interv Neuroradiol, 2011, 17(4):442-451.] - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous